1. T Ciuleanu T Brodowicz C Zielinski et al.2009 Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 1432 1440.

1. T Ciuleanu T Brodowicz C Zielinski 2009 Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 1432 1440.)| false
• Search Google Scholar
• Export Citation

2. LE Coate T John MS Tsao FA Shepherd 2009 Molecular predictive and prognostic markers in non-small-cell lung cancer Lancet Oncol 10 1001 1010.

2. LE Coate T John MS Tsao FA Shepherd 2009 Molecular predictive and prognostic markers in non-small-cell lung cancer Lancet Oncol 10 1001 1010.)| false
• Search Google Scholar
• Export Citation

3. DA Eberhard G Giaccone BE Johnson 2008 Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting J Clin Oncol 26 983 994.

3. DA Eberhard G Giaccone BE Johnson 2008 Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting J Clin Oncol 26 983 994.)| false
• Search Google Scholar
• Export Citation

4. AF Gazdar 2009 Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 28 24 31.

4. AF Gazdar 2009 Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 28 24 31.)| false
• Search Google Scholar
• Export Citation

5. R Gupta AM Dastane R McKenna Jr AM Marchevsky 2009 The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current “best evidence” with meta-analysis Hum Pathol 40 356 365.

5. R Gupta AM Dastane R McKenna Jr AM Marchevsky 2009 The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current “best evidence” with meta-analysis Hum Pathol 40 356 365.)| false
• Search Google Scholar
• Export Citation

6. L Horn W Pao 2009 EML4-ALK: Homing in on a new target in non-small-cell lung cancer J Clin Oncol 27 4232 4235.

6. L Horn W Pao 2009 EML4-ALK: Homing in on a new target in non-small-cell lung cancer J Clin Oncol 27 4232 4235.)| false
• Search Google Scholar
• Export Citation

7. A Jemal R Siegel E Ward et al.2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96.

7. A Jemal R Siegel E Ward 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96.)| false
• Search Google Scholar
• Export Citation

8. KM Kerr 2009 Pulmonary adenocarcinomas: classification and reporting Histopathology 54 12 27.

8. KM Kerr 2009 Pulmonary adenocarcinomas: classification and reporting Histopathology 54 12 27.)| false
• Search Google Scholar
• Export Citation

9. L Kopper J Tímár 2009 A KRAS mutációjának hazai körvizsgálata (validálási vizsgálat) Magyar Onkológia 53 361 366.

9. L Kopper J Tímár 2009 A KRAS mutációjának hazai körvizsgálata (validálási vizsgálat) Magyar Onkológia 53 361 366.)| false
• Search Google Scholar
• Export Citation

10. H Linardou IJ Dahabreh D Kanaloupiti et al.2008 Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 962 972.

10. H Linardou IJ Dahabreh D Kanaloupiti 2008 Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 962 972.)| false
• Search Google Scholar
• Export Citation

11. TS Mok YL Wu S Thongprasert et al.2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947 957.

11. TS Mok YL Wu S Thongprasert 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947 957.)| false
• Search Google Scholar
• Export Citation

12. G Ostoros V Sárosi G Losonczy et al.2009 The effectiveness of erlotinib (Tarceva) treatment in KRAS negative lung adenocarcinomas – preliminary results of an observational cohort study Eur J Cancer Suppl7/2 559.

12. G Ostoros V Sárosi G Losonczy 2009 The effectiveness of erlotinib (Tarceva) treatment in KRAS negative lung adenocarcinomas – preliminary results of an observational cohort study Eur J Cancer Suppl7/2 559.)| false
• Search Google Scholar
• Export Citation

13. F Pintér J Pápay A Almási et al.2008 Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry J Mol Diag 10 160 168.

13. F Pintér J Pápay A Almási 2008 Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry J Mol Diag 10 160 168.)| false
• Search Google Scholar
• Export Citation

14. R Pirker JR Pereira A Szczesna FLEX Study Team et al.2009 Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 1525 1531.

14. R Pirker JR Pereira A Szczesna FLEX Study Team 2009 Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 1525 1531.)| false
• Search Google Scholar
• Export Citation

15. M Reck J von Pawel P Zatloukal et al.2009 Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL J Clin Oncol 27 1227 1234.

15. M Reck J von Pawel P Zatloukal 2009 Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL J Clin Oncol 27 1227 1234.)| false
• Search Google Scholar
• Export Citation

16. GJ Riely J Marks W Pao 2009 KRAS mutations in non-small cell lung cancer Proc Am Thorac Soc 6 201 205.

16. GJ Riely J Marks W Pao 2009 KRAS mutations in non-small cell lung cancer Proc Am Thorac Soc 6 201 205.)| false
• Search Google Scholar
• Export Citation

17. A Sandler R Gray MC Perry et al.2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550.

17. A Sandler R Gray MC Perry 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550.)| false
• Search Google Scholar
• Export Citation

18. G Scagliotti N Hanna F Fossella et al.2009 The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 253 263.

18. G Scagliotti N Hanna F Fossella 2009 The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 253 263.)| false
• Search Google Scholar
• Export Citation

19. GV Scagliotti P Parikh J von Pawel et al.2008 Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 3543 3551.

19. GV Scagliotti P Parikh J von Pawel 2008 Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 3543 3551.)| false
• Search Google Scholar
• Export Citation

20. Tímár J , Fillinger J. Pathology of lung cancer: histology, cytology, immunohistochemistry and molecular pathology. European Respiratory Monograph 48: Interventional Pulmonology, EDU-9919, 2010 (in press).

20. Tímár J , FillingerJ.Pathology of lung cancer: histology, cytology, immunohistochemistry and molecular pathology. European Respiratory Monograph48: Interventional Pulmonology, EDU-9919, 2010 (in press).)| false
• Search Google Scholar
• Export Citation

21. JH van Krieken A Jung T Kirchner et al.2008 KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for European quality assurance program Virchows Arch 453 417 431.

21. JH van Krieken A Jung T Kirchner 2008 KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for European quality assurance program Virchows Arch 453 417 431.)| false
• Search Google Scholar
• Export Citation